MedTrace Logo

Optimizing the Use of Morphine in Pre-Term Neonates

NCT00494429 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2016-07-27

No results posted yet for this study

Summary

The purpose of this study is to improve the dosing of morphine in critically ill premature neonates.

Conditions

  • Premature Neonates

Interventions

DRUG

Morphine

Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.

DRUG

Morphine

Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • John van den Anker

    lead OTHER

Principal Investigators

  • John N. van den Anker, M.D., Ph.D. · Children's National Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Weeks
Max Age
32 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2014-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494429 on ClinicalTrials.gov